This Special Communication discusses case-referenced consensus and evidence-based guidelines to inform clinical practice in unresectable locally advanced NSCLC. ja.ma/4aL5YND

ARS Appropriateness Use Criteria for Unresectable Locally Advanced Non–Small Cell Lung Cancer

Strong push for IMRT; discussion of nuances for PD-L1 negative / EGFR mutant / poor performance status or pulmonary function

Kudos to George Rodrigues and Kristin Higgins!

jamanetwork.com/journals/jamao…

🔥🚨OncoAlert Hot Off the Press
BIG NEWS Press Release by AstraZeneca

#ADRIATIC phase 3 trial of #Durvalumab vs #Placebo after concurrent chemoradiotherapy
in pts with limited-stage #SmallCell #LungCancer met dual primary endpoints of ⬆️ #OS & ⬆️ #PFS
👇🏼
astrazeneca.com/media-centre/p…

Real-World Data: Applications and Relevance to Cancer Clinical Trials

pubmed.ncbi.nlm.nih.gov/37684067/

We compare randomized trials to retrospective data from US national cancer databases (eg, SEER, NCDB).

Courtney Pisano, DO,MS,MPH Poom Khunsriraksakul 🇹🇭 Daniel E Spratt Henry S. Park, MD, MPH Yilun Sun Ming Wang_CWRU

YALE MEN'S BASKETBALL WINS ITS SECOND NCAA TOURNAMENT GAME IN SCHOOL HISTORY

This story highlights the incredible resilience that James has shown over the past year ever since we had the good fortune of matching him. We are so lucky to have him joining our Yale Radiation Oncology Residency program in July and caring for patients with cancer! Yale Cancer Center Yale School of Medicine UMass Chan Medical School

Congratulations to our fantastic team of dosimetrists, physicists, therapists, nurses, residents, and hospital leaders for successfully becoming the world's 5th center to treat lung and bone tumors with biology-guided radiotherapy! Yale Radiation Oncology Residency Yale Cancer Center Yale School of Medicine RefleXion Medical

Dr. Jeff Bradley, MD presents results from PACIFIC-2 at #ELCC24 . Included pts with unresectable stage III NSCLC with randomization to chemoradiation with concurrent durvalumab/placebo followed by durvalumab/placebo consolidation. Note this was done before OS from PACIFIC known.

THE WINNING BASKET

#ThisIsYale

Today has been one of the most exciting days of my life as I #matched at my first choice residency program 🤩. I’m beyond estatic to be joining the Harvard Radiation Oncology Residency Program residency program Mass General Brigham! So grateful to support from Yale MSTP, PD Soros Fellowships, family, friends and mentors 🙏!!!

YSM's MD #Classof24 got the final word on where they're headed for #residency next year at today's #MatchDay ceremony. Our new graduates will be completing their #training at centers and hospitals from #CoasttoCoast and beyond.

Congrats to these 3 awesome incoming residents Yale Radiation Oncology Residency! And to all of our other fantastic Yale School of Medicine students who matched today! So proud of you all.

On Match day, I am always reminded how grateful and proud I am to be a part of this Yale Radiation Oncology Residency family. I hope that every matching med student today finds the nurturing, inspiring, motivating, and a little bit silly family that we have in this group ❤️

1/ Thank you 🙏🏾, patients, families, and investigators, for contributing to the SEISMIC 🫁trial out now The Lancet Respiratory Medicine - shorturl.at/qxMUY. Led by 🫁Daniel Steinfort, this international multicentre recruited n=155 trial from 🇦🇺, 🇨🇦, 🇺🇸, 🇳🇱 #radonc CTSurgSocMedNetwork Peter Mac Radiation Oncology

🚨 Hot off the press in JAMA Oncology: our ASPIRE-ILD trial testing SABR in patients with early NSCLC and interstitial lung disease.

Thanks to all our patients and participating centres!

jamanetwork.com/journals/jamao…

Thank you for the invitation! I very much enjoyed spending time with your engaging faculty and residents.

Let’s chat about arytenoid sparing IMRT for early larynx cancer at #HNCS24 !
Henry S. Park, MD, MPH Yale Radiation Oncology Residency